| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome.
|
Nat Genet
|
2011
|
2.74
|
|
2
|
Testing association of a pathway with survival using gene expression data.
|
Bioinformatics
|
2005
|
2.57
|
|
3
|
Tumor-associated zinc finger mutations in the CTCF transcription factor selectively alter tts DNA-binding specificity.
|
Cancer Res
|
2002
|
2.52
|
|
4
|
Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma.
|
J Pathol
|
2010
|
2.17
|
|
5
|
Modulation of the osteosarcoma expression phenotype by microRNAs.
|
PLoS One
|
2012
|
2.06
|
|
6
|
Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2.
|
J Pathol
|
2009
|
1.96
|
|
7
|
Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer.
|
Cancer Res
|
2007
|
1.63
|
|
8
|
Multiplex ligation-dependent probe amplification for the detection of 1p and 19q chromosomal loss in oligodendroglial tumors.
|
Brain Pathol
|
2005
|
1.54
|
|
9
|
Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents.
|
Clin Cancer Res
|
2011
|
1.53
|
|
10
|
Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort.
|
Genes Chromosomes Cancer
|
2010
|
1.50
|
|
11
|
Annexin A1 regulates TGF-beta signaling and promotes metastasis formation of basal-like breast cancer cells.
|
Proc Natl Acad Sci U S A
|
2010
|
1.42
|
|
12
|
The role of EXT1 in nonhereditary osteochondroma: identification of homozygous deletions.
|
J Natl Cancer Inst
|
2007
|
1.37
|
|
13
|
Functional characterization of osteosarcoma cell lines provides representative models to study the human disease.
|
Lab Invest
|
2011
|
1.32
|
|
14
|
Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment.
|
Lancet Oncol
|
2005
|
1.30
|
|
15
|
CBFA2T3 (MTG16) is a putative breast tumor suppressor gene from the breast cancer loss of heterozygosity region at 16q24.3.
|
Cancer Res
|
2002
|
1.24
|
|
16
|
Identification of markers to characterize and sort human articular chondrocytes with enhanced in vitro chondrogenic capacity.
|
Arthritis Rheum
|
2007
|
1.20
|
|
17
|
Absence of IHH and retention of PTHrP signalling in enchondromas and central chondrosarcomas.
|
J Pathol
|
2005
|
1.16
|
|
18
|
Desmoplastic fibroma of bone: an immunohistochemical study including beta-catenin expression and mutational analysis for beta-catenin.
|
Hum Pathol
|
2005
|
1.15
|
|
19
|
MicroRNAs at the human 14q32 locus have prognostic significance in osteosarcoma.
|
Orphanet J Rare Dis
|
2013
|
1.13
|
|
20
|
CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent, multicenter validation study.
|
Cancer
|
2013
|
1.13
|
|
21
|
Integrative analysis reveals relationships of genetic and epigenetic alterations in osteosarcoma.
|
PLoS One
|
2012
|
1.13
|
|
22
|
Mutation Analysis of H3F3A and H3F3B as a Diagnostic Tool for Giant Cell Tumor of Bone and Chondroblastoma.
|
Am J Surg Pathol
|
2015
|
1.13
|
|
23
|
Genomic profiling of chondrosarcoma: chromosomal patterns in central and peripheral tumors.
|
Clin Cancer Res
|
2009
|
1.12
|
|
24
|
Identification of osteosarcoma driver genes by integrative analysis of copy number and gene expression data.
|
Genes Chromosomes Cancer
|
2012
|
1.11
|
|
25
|
Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancer.
|
Cancer Res
|
2012
|
1.09
|
|
26
|
FBXO31 is the chromosome 16q24.3 senescence gene, a candidate breast tumor suppressor, and a component of an SCF complex.
|
Cancer Res
|
2005
|
1.09
|
|
27
|
Molecular analysis of the INK4A/INK4A-ARF gene locus in conventional (central) chondrosarcomas and enchondromas: indication of an important gene for tumour progression.
|
J Pathol
|
2004
|
1.08
|
|
28
|
Hypoxia-inducible factor regulates osteoclast-mediated bone resorption: role of angiopoietin-like 4.
|
FASEB J
|
2010
|
1.05
|
|
29
|
Central chondrosarcoma progression is associated with pRb pathway alterations: CDK4 down-regulation and p16 overexpression inhibit cell growth in vitro.
|
J Cell Mol Med
|
2008
|
1.04
|
|
30
|
IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma.
|
BMC Cancer
|
2013
|
1.03
|
|
31
|
Aberrant heparan sulfate proteoglycan localization, despite normal exostosin, in central chondrosarcoma.
|
Am J Pathol
|
2009
|
1.00
|
|
32
|
Molecular pathology and its diagnostic use in bone tumors.
|
Cancer Genet
|
2012
|
0.99
|
|
33
|
mRNA expression profiles of primary high-grade central osteosarcoma are preserved in cell lines and xenografts.
|
BMC Med Genomics
|
2011
|
0.97
|
|
34
|
Sensitive and specific KRAS somatic mutation analysis on whole-genome amplified DNA from archival tissues.
|
J Mol Diagn
|
2009
|
0.96
|
|
35
|
Evaluation of high-resolution microarray platforms for genomic profiling of bone tumours.
|
BMC Res Notes
|
2010
|
0.96
|
|
36
|
Expression analysis of candidate breast tumour suppressor genes on chromosome 16q.
|
Breast Cancer Res
|
2005
|
0.96
|
|
37
|
Cellular/intramuscular myxoma and grade I myxofibrosarcoma are characterized by distinct genetic alterations and specific composition of their extracellular matrix.
|
J Cell Mol Med
|
2009
|
0.96
|
|
38
|
Mediator complex subunit 12 exon 2 mutation analysis in different subtypes of smooth muscle tumors confirms genetic heterogeneity.
|
Hum Pathol
|
2013
|
0.95
|
|
39
|
Mesenchymal stem cell transformation and sarcoma genesis.
|
Clin Sarcoma Res
|
2013
|
0.95
|
|
40
|
The activities of Smad and Gli mediated signalling pathways in high-grade conventional osteosarcoma.
|
Eur J Cancer
|
2012
|
0.94
|
|
41
|
Characterization of familial non-BRCA1/2 breast tumors by loss of heterozygosity and immunophenotyping.
|
Clin Cancer Res
|
2006
|
0.93
|
|
42
|
The use of Bcl-2 and PTHLH immunohistochemistry in the diagnosis of peripheral chondrosarcoma in a clinicopathological setting.
|
Virchows Arch
|
2005
|
0.93
|
|
43
|
Small deletions but not methylation underlie CDKN2A/p16 loss of expression in conventional osteosarcoma.
|
Genes Chromosomes Cancer
|
2010
|
0.93
|
|
44
|
Immune response to RB1-regulated senescence limits radiation-induced osteosarcoma formation.
|
J Clin Invest
|
2013
|
0.92
|
|
45
|
Molecular genetic evidence for monoclonal origin of bilateral ovarian serous borderline tumors.
|
Am J Pathol
|
2003
|
0.91
|
|
46
|
Update on targets and novel treatment options for high-grade osteosarcoma and chondrosarcoma.
|
Hematol Oncol Clin North Am
|
2013
|
0.91
|
|
47
|
Infiltrating leukocytes confound the detection of E-cadherin promoter methylation in tumors.
|
Biochem Biophys Res Commun
|
2004
|
0.91
|
|
48
|
MLPAinter for MLPA interpretation: an integrated approach for the analysis, visualisation and data management of Multiplex Ligation-dependent Probe Amplification.
|
BMC Bioinformatics
|
2010
|
0.91
|
|
49
|
Genome-wide analyses on high-grade osteosarcoma: making sense of a genomically most unstable tumor.
|
Int J Cancer
|
2013
|
0.91
|
|
50
|
Targeting JNK-interacting-protein-1 (JIP1) sensitises osteosarcoma to doxorubicin.
|
Oncotarget
|
2012
|
0.90
|
|
51
|
Visualization of regional gene expression biases by microarray data sorting.
|
Biotechniques
|
2004
|
0.90
|
|
52
|
Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-γ.
|
J Exp Clin Cancer Res
|
2014
|
0.89
|
|
53
|
Functional allelic loss detected at the protein level in archival human tumours using allele-specific E-cadherin monoclonal antibodies.
|
J Pathol
|
2002
|
0.88
|
|
54
|
Osteosarcoma models: from cell lines to zebrafish.
|
Sarcoma
|
2012
|
0.87
|
|
55
|
Defining regions of loss of heterozygosity of 16q in breast cancer cell lines.
|
Cancer Genet Cytogenet
|
2002
|
0.86
|
|
56
|
Expression of aromatase and estrogen receptor alpha in chondrosarcoma, but no beneficial effect of inhibiting estrogen signaling both in vitro and in vivo.
|
Clin Sarcoma Res
|
2011
|
0.84
|
|
57
|
BMP and TGFbeta pathways in human central chondrosarcoma: enhanced endoglin and Smad 1 signaling in high grade tumors.
|
BMC Cancer
|
2012
|
0.84
|
|
58
|
Recurrent chromosome 22 deletions in osteoblastoma affect inhibitors of the Wnt/beta-catenin signaling pathway.
|
PLoS One
|
2013
|
0.84
|
|
59
|
An osteosarcoma zebrafish model implicates Mmp-19 and Ets-1 as well as reduced host immune response in angiogenesis and migration.
|
J Pathol
|
2012
|
0.80
|
|
60
|
Tissue factor associates with survival and regulates tumour progression in osteosarcoma.
|
Thromb Haemost
|
2016
|
0.76
|
|
61
|
Mutations affecting BRAF, EGFR, PIK3CA, and KRAS are not associated with sporadic vestibular schwannomas.
|
Virchows Arch
|
2012
|
0.76
|
|
62
|
Radiation-induced Sarcomas Occurring in Desmoid-type Fibromatosis Are Not Always Derived From the Primary Tumor.
|
Am J Surg Pathol
|
2015
|
0.75
|